International webinar on Engineering Next-Generation Therapeutics for Cancer”

Official Website →

Event Details

Dr. Shiladitya Sengupta is an Associate Professor of Medicine at Harvard Medical School and Co-Director of the Center for Engineered Therapeutics at the Brigham and Women’s Hospital. He is a Principal Investigator at the Dana-Farber Cancer Institute and Harvard-MIT Division of Health Science and Technology. His laboratory focuses on using nano- and microscale technologies to study cancer biology, especially tumor-stroma interactions. He invented the first layer-by-layer nanoparticle and demonstrated its use in spatiotemporally targeting angiogenesis and cancer cells, which led to founding of Cerulean Pharmaceuticals (NASDAQ-CRLX).
Dr. Sengupta received his PhD in Pharmacology from the University of Cambridge, where he was a Nehru and British Chevening Scholar at Trinity College. He has received the TR35 Innovator award from MIT Technology Review Magazine, an honor given to the top 35 innovators worldwide by MIT Technology Review magazine, and is a recipient of the Era of Hope Scholar Award from the US Department of Defense, Coulter Foundation Career Award, and Young Scientist awards from the American Society for Pharmacology and Experimental Therapeutics.

Sengupta’s lab is exploring new frontiers in using the immune system to target cancer. They are studying the mechanisms underlying the interactions between cancer and immune cells. They demonstrated, for the first time, that the dual targeting of SIRP and CSF1R using a novel engineered therapeutic allows macrophages to better phagocytose cancer cells (Nature Biomedical Engineering, 2018). They were the first to design an activatable reporter nanoparticle to monitor the anti-cancer efficacy of an immune checkpoint inhibitor in real-time (PNAS 2016).Using microfluidics platforms and tumor explants, they are studying how immune cells be recruited into tumors. They are also exploring the roles of B cells in tumor immune response. Using a computational design platform, they recently designed a new linker for engineering antibody drug conjugates for treatment of cancer (Nature Biomedical Engineering, 2019).

Listed on .

JavaScript is required to reveal this email address.

List an Event →